Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shuanghuanglian Inhalation Solution is a traditional Chinese medicine (TCM) candidate being developed by Beijing Yingkerei Pharmaceutical Technology for the treatment of respiratory infections. The formulation is a nebulized solution of the classic Shuanghuanglian formula, which is composed of extracts from *Lonicera japonica* (Japanese Honeysuckle), *Scutellaria baicalensis* (Baikal Skullcap), and *Forsythia suspensa* (Weeping Forsythia). This combination is traditionally used for its broad-spectrum antiviral, antibacterial, and anti-inflammatory properties. By delivering the medication via inhalation, the treatment aims to achieve high local concentrations in the respiratory tract, potentially improving efficacy and safety for conditions such as acute bronchitis and upper respiratory tract infections. It is currently in the preclinical stage of development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on shuanghuanglian inhalation solution.